内镜下袖状胃成形术与腹腔镜袖状胃切除术在伴非酒精性脂肪性肝炎的肥胖受试者中的疗效与安全性:随机对照试验研究方案(TESLA-NASH研究)
TESLA-NASH研究是一项随机、对照、开放标签、单中心、器械类临床试验,计划纳入30例伴代谢综合征和NASH的肥胖患者,按1:1随机分配至内镜下袖状胃成形术(ESG)组或腹腔镜袖状胃切除术(LSG)组,旨在评估和比较两种术式改善肝脏组织学的疗效与安全性。
要点
- NASH标准治疗为饮食运动减重,但不足25%受试者能达到目标体重下降。
- LSG是常见减重手术,减重有效并改善NASH等合并症,但伴多种术后并发症。
- ESG作为新兴内镜减重技术,与LSG相比疗效和安全性尚不明确。
核心结论
- 该研究旨在评估和比较ESG与LSG在伴代谢综合征和NASH的肥胖患者中改善肝脏组织学的疗效与安全性;ESG与LSG相比的疗效和安全性尚不明确。
研究设计与样本
- TESLA-NASH研究为随机、对照、开放标签、单中心、器械类临床试验。
- 计划共纳入30例伴代谢综合征和NASH的肥胖患者,按1:1随机分配至实验组或对照组。
- 试验注册号ClinicalTrials.gov NCT04060368,注册日期2019年11月15日。
主要发现
- NASH常与肥胖相关,标准治疗为饮食和运动减重;体重下降一定百分比与肝脏组织学和分析异常的改善相关,但不足25%的受试者达到该目标。
- LSG是减重手术中最常见的术式,可有效减重并改善NASH等合并症,但与多种术后并发症相关。
- 内镜减重技术作为对抗肥胖的新工具正在兴起,为患者提供替代更具侵入性手术的选择,但其与LSG相比的疗效和安全性尚不明确。
- ESG是最有前景的新型内镜干预之一,主要针对轻至中度肥胖患者,但目前尚无指南明确其适用标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is frequently associated with obesity, and its standard treatment is weight loss with diet and exercise; a dy% weight reduction has been associated with improvement in liver histological and analytical abnormalities. However, less than 25% of subjects achieve this goal. Laparoscopic sleeve gastrectomy (LSG) represents the most common procedure of bariatric surgery, providing effective weight loss and improvement in comorbidities such as NASH, but it is associated with several postoperative complications. Endoscopic bariatric techniques are currently on the rise as a new tool in the fight against obesity, offering patients an alternative to more invasive surgery. However, their efficacy and safety compared with LSG is unclear. METHODS: The TESLA-NASH study is a randomized, controlled, open-label, unicentric clinical trial with a medical device. The aim of this study is to evaluate and compare the efficacy and safety of endoscopic sleeve gastroplasty (ESG) versus laparoscopic sleeve gastrectomy (LSG) in liver histology improvement of patients with obesity +/- metabolic syndrome and NASH. A total of 30 patients will be randomized 1:1 to the experimental or control group. DISCUSSION: LSG is an effective treatment for weight reduction and for the remission of hepatic alterations. However, LSG is associated with acute and chronic postoperative complications. Bariatric endoscopic techniques promise less invasive and more cost-effective approaches to the treatment of obesity and metabolic comorbidities. ESG represents one of the most promising novel endoscopic interventions and it is mainly proposed for patients with mild-to-moderate obesity, but there are still no guidelines that specify its applicability criteria. This clinical trial will help us apply different tactics to the treatment of obesity and NASH. TRIAL REGISTRATION: ClinicalTrials.gov NCT04060368. Registered on Nov 15, 2019.
引用
- Lavín-Alconero L, Fernández-Lanas T, Iruzubieta-Coz P, et al. Efficacy and safety of endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy in obese subjects with Non-Alcoholic SteatoHepatitis (NASH): study protocol for a randomized controlled trial (TESLA-NASH study). Trials. 2021. PMID: 34717726. doi:10.1186/s13063-021-05695-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。